Navigation Links
Ibuprofen destroys aspirin's positive effect on stroke risk
Date:3/12/2008

BUFFALO, N.Y. -- Stroke patients who use ibuprofen for arthritis pain or other conditions while taking aspirin to reduce the risk of a second stroke undermine aspirins ability to act as an anti-platelet agent, researchers at the University at Buffalo have shown.

In a cohort of patients seen by physicians at two offices of the Dent Neurologic Institute, 28 patients were identified as taking both aspirin and ibuprofen (a nonsteroidal anti-inflammatory drug, or NSAID) daily and all were found to have no anti-platelet effect from their daily aspirin.

Thirteen of these patients were being seen because they had a second stroke/TIA while taking aspirin and a NSAID, and were platelet non-responsive to aspirin (aspirin resistant) at the time of that stroke.

The researchers found that when 18 of the 28 patients returned for a second neurological visit after discontinuing NSAID use and were tested again, all had regained their aspirin sensitivity and its ability to prevent blood platelets from aggregating and blocking arteries.

The study is the first to show the clinical consequences of the aspirin/NSAID interaction in patients being treated for prevention of a second stroke, and presents a possible explanation of the mechanism of action.

The Food and Drug Administration currently warns that ibuprofen might make aspirin less effective, but states that the clinical implications of the interaction have not been evaluated.

This interaction between aspirin and ibuprofen or prescription NSAIDs is one of the best-known, but well-kept secrets in stroke medicine, said Francis M. Gengo, Pharm.D., lead researcher on the study.

Its unfortunate that clinicians and patients often are unaware of this interaction. Whatever number of patients who have had strokes because of the interaction between aspirin and NSAIDs, those strokes were preventable.

Gengo is professor of neurology in the UB School of Medicine and Biomedical Sciences and professor of pharmacy practice in the UB School of Pharmacy and Pharmaceutical Sciences. Results of the study were published in the January issue of the Journal of Clinical Pharmacology.

We first looked at this issue way back in 1992 in a study conducted in normal volunteers, but it was published as an abstract only, he said. We never followed through with a manuscript, but another group published an elegant study in the New England Journal of Medicine showing this interaction at least seven years ago.

When we began to assess this in our stroke patients, a surprisingly high percentage of a group of 653 patients, around 17 percent, were taking aspirin plus Motrin [a brand of ibuprofen].

The prescription medication Aggrenox, which also is used for secondary stroke prevention and contains aspirin and extended release dipyridamole, is affected the same way as aspirin, Gengo continued. In preventing strokes, it is statistically a little better than aspirin but more expensive.

However, one of the most common side effects when you first start taking Aggrenox is headache, so some physicians, pharmacists or physician assistants tell patients to take a Motrin so they dont get a headache. This likely would negate the effects of the aspirin and extended release dipyridamole. Those patients might as well take this expensive drug and flush it down the toilet.

Gengo and colleagues verified with urine testing that all 18 patients, six men and 12 women, were taking their aspirin or aspirin and extended release dipyridamole as directed. Information on the concomitant use of NSAIDS was obtained from patient interviews. Data from the earlier healthy volunteer study showed the magnitude and time course of each drug administered separately, as well as in combination.

The UB study provides important information, Gengo noted, because in most previous studies, measurements were taken only at one point in time, and that time point may have been during the 4-6 hour window when concentrations of NSAIDS were sufficiently high to inhibit aggregation.

Our data report the entire time course of this interaction, he said. The results showed that platelets resumed aggregating within 4-6 hours when aspirin and ibuprofen were taken close together, leaving patients with no anti-platelet effect for 18-20 hours a day. Normally, a single dose of aspirin has an effect on platelet aggregation for 72-96 hours, Gengo said.

When I lecture to pharmacy students, I tell them Please, you have a responsibility to the patients you care for. When you counsel a patient taking aspirin/extended release dipyrdamole to lower stroke risk, tell patients they may have some transient headaches, but to avoid ibuprofen. You may have prevented that patient from having another stroke.


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-5000 x1417
University at Buffalo
Source:Eurekalert

Related medicine news :

1. Ibuprofen Preserves Lung Function in Kids With Cystic Fibrosis
2. Ibuprofen associated with slower lung function decline in children with cystic fibrosis
3. Albemarle to Increase Price of Ibuprofen
4. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
5. Researchers train the immune system to deliver virus that destroys cancer in lab models
6. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
7. Positive results from phase 1 clinical trials of cuprindro
8. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive
9. HPV-positive head and neck cancer patients fare better than HPV-negative patients
10. HPV-Positive Head and Neck Cancers Fare Better
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced that ... donate to Give To Cure’s campaign that is crowdfunding clinical trials to help find ... share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... At its ... of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds ... of the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat ...
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, it ... illness. Migraines are a severe form of a headache and often are accompanied by ... pain on their worst enemy, the feeling can last for many hours and be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been ... user interface design and the developer has fixed known bugs within the app. Calls ... on their phone while not consuming any of their device’s battery power or memory. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LODI, N.J. , Feb. 4, 2016  Montoya ... Pinnacle Professional in the field of Pharmaceuticals. Montoya is ... . ... and supplies, Becton Dickinson provides healthcare institutions, ... medical equipment throughout fifty countries across the globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ... solutions to healthcare systems, today announced results for its ... --> --> GAAP results: ... million, up $5.1 million or 4.1% from the third ... from the fourth quarter of 2014. Revenue for the ...
Breaking Medicine Technology: